We are live on ! Find out more
IMVT icon

Immunovant

24 hedge funds and large institutions have $176M invested in Immunovant in 2019 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

382% more capital invested

Capital invested by funds: $36.6M → $176M (+$140M)

91% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 11

71% more funds holding

Funds holding: 1424 (+10)

5.02% less ownership

Funds ownership: 25.6%20.58% (-5%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
24
Holders Change
+10
Holders Change %
+71.43%
% of All Funds
0.47%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
21
Increased
Reduced
2
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
DKCM
26
Davidson Kempner Capital Management
New York
-$5.13M -524,400 Closed
JGC
27
J. Goldman & Co
New York
-$3.01M -300,000 Closed
WAM
28
Wolverine Asset Management
Illinois
-$1.76M -176,157 Closed
Walleye Trading
29
Walleye Trading
New York
-$1.28M -130,727 Closed
HIM
30
HGC Investment Management
Ontario, Canada
-$1.07M -106,627 Closed
KPF
31
K2 Principal Fund
Ontario, Canada
-$1.01M -102,926 Closed
BCM
32
Basso Capital Management
Connecticut
-$746K -74,455 Closed
WAM
33
Weiss Asset Management
Massachusetts
-$503K -50,400 Closed
MF
34
Magnetar Financial
Illinois
-$500K -50,000 Closed
PAM
35
Panagora Asset Management
Massachusetts
-$8K -820 Closed

IMVT Hedge Fund Activity: Q4 2019 in Review

24 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2019, worth a combined $176M — up 382% from $36.6M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new IMVT positions and 11 closed out — a net gain of 10 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $49.6M. The largest seller was 683 Capital Management, cutting an estimated $8.81M.

  • 24 institutional investors held Immunovant (IMVT) as of Q4 2019, up from 14 in Q3 2019.
  • Funds reported $176M of Immunovant stock for Q4 2019, up 382% quarter-over-quarter.
  • 21 funds opened new Immunovant positions in Q4 2019 and 11 closed out, a net change of +10 holders.
  • The largest Immunovant buyer in Q4 2019 was RTW Investments, an estimated $49.6M added.
  • The largest Immunovant seller in Q4 2019 was 683 Capital Management, an estimated $8.81M sold.

Based on aggregated 13F filings for Q4 2019.